Cost-utility analysis of prophylaxis versus treatment on demand in severe hemophilia A

ClinicoEconomics and Outcomes Research

Volumn 3, Issue 1, 2011, Pages 55-61

  Colombo, Giorgio L ^a,b   di Matteo, Sergio ^b   Elisa Mancuso, Maria ^c   Santagostino, Elena ^c  

^a UNIVERSITY OF PAVIA   (Italy)

^b SAVE Studi Analisi Valutazioni Economiche   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Cost utility; Factor VIII; Hemophilia; Prophylaxis; Quality of life; Treatment on demand

Indexed keywords

BLOOD CLOTTING FACTOR 8;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE SEVERITY; HEALTH CARE COST; HEALTH CARE QUALITY; HEMOPHILIA A; HIDDEN MARKOV MODEL; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PROPHYLAXIS; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SENSITIVITY ANALYSIS;

EID: 79952927760     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/CEOR.S16670     Document Type: Article

References (22)

1. Ljung R. Prophylactic therapy in hemophilia. Blood Rev. 2009;23: 267-274.
2. Pipe S. Antihemophilic factor (recombinant) plasma/albumin-free method for the management and prevention of bleeding episodes in patients with hemophilia A. Biologics. 2009;3:117-125.
3. Miners A. Revisiting the cost-effectiveness of primary prophylaxis with clotting factor for the treatment of severe haemophilia A. Haemophilia.2009;15(4):881-887.
4. Gringeri A. Mantovani LG, Scalone L, Mannucci PM, For the COCIS Study Group; Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group.2003;102(7):2358-2363.
5. Donadel-Claeyssens S, European Paediatric Network for Haemophilia Management; Current co-ordinated activities of the PEDNET (European Paediatric Network for Haemophilia Management). Haemophilia. 2006; 12(2):124-127
6. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357(6):535-544.
7. Miners AH, Sabin CA, Tolley KH, Lee CA. Cost-utility analysis of primary prophylaxis versus treatment on-demand for individuals with severe haemophilia. Pharmacoeconomics. 2002;20(11):759-774.
8. Drummond MF, Schulpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes.3rd ed. Oxford: Oxford University Press; 2005.
9. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13(4):322-338.
10. Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics. 1998;13(4):397-409.
11. Demo.istat.it [homepage on the internet]. Italian National Institute of Statistics. Age specific death rates by gender [updated 2007]. http://demo.istat.it/unitav/index.html?lingua=ita. Accessed January 11, 2010.
12. Salute.gov.it. [homepage on the internet]. Italian Ministry of Health. http://www.salute.gov.it/ricoveriOspedalieri/ric_informazioni/default.jsp. Accessed February 12, 2010.
13. Miners AH, Sabin CA, Tolley KH, Jenkinson C, Kind P, Lee CA. Assessing health-related quality-of-life in individuals with haemophilia. Haemophilia. 1999;5(6):378-385.
14. Laupacis A, Bourne R, Rorabeck C, et al. The effect of elective total hip replacement on health-related quality of life. J Bone Joint Surg Am.1993;75(11):1619-1626.
15. Santagostino E, Mannucci PM, Bianchi Bonomi A. Guidelines on replacement therapy for haemophilia and inherited coagulation disorders in Italy. Haemophilia. 2000;6(1):1-10.
16. Tagliaferri A, Franchini M, Coppola A, et al. Effects of secondary prophylaxis started in adolescent and adult haemophiliacs. Haemophilia.2008;14(5):945-951.
17. Informatore Farmaceutico. Elsevier; 2010.
18. Geraghty S, Dunkley T, Harrington C, Lindvall K, Maahs J, Sek J. Practice patterns in haemophilia A therapy - global progress towards optimal care. Haemophilia. 2006;12(1):75-81.
19. C, Ravasio R. Come valutare i risultati di uno studio farmacoeconomico? PharmacoEconomics - Italian Research Articles.2004;(3):121-130.
20. Messori A, Santarlasci B, Trippoli S, Vaiani M. Controvalore economico del farmaco e beneficio clinico: Stato dell'arte della metodologia e applicazione di un algoritmo farmacoeconomico. PharmacoEconomics - Italian Research Articles. 2003;5:53-67.
21. Associazione Italiana di Economia Sanitaria (AIES). Proposta di linee guida per la valutazione economica degli interventi sanitari. PharmacoEconomics - Italian Research Articles. 2009;11:83-93.
22. A. Prospective controlled studies on prophylaxis: an Italian approach. Haemophilia. 2003;9 Suppl 1:S38-S42.